Protean 600+ is a latest generation comprehensive genomic profiling test, that uses a single tumor specimen to evaluate over 600 genes.
The Protean 600+ test is part of the Protean MAPS® system, and is designed to provide the most comprehensive information regarding actionable targets in a specimen, to identify approved treatments and clinical trial opportunities.
Protean 600+ can be used for any cancer type but is ideal for analysis of solid tumors such as breast, lung, colon, pancreas, prostate, sarcoma, and others.
Protean 600+ Highlights:
Evaluates both DNA & RNA, and detects key gene fusions: ALK, RET, ROS, NTRK1,2,3, etc.
Uncovers SNP mutations, deletions, fusions, and copy number variants
Measures microsatellite instability (MSI) and tumor mutational burden (TMB)
Includes key inherited cancer genes
Can uncover important germ line variants
Uses a small amount of FFPE Materials
Detection of exon skipping, alternative splicing, and gene amplifications
The Protean 600+ report provides the information you need in a clear and easy to understand format.
Treatment recommendations organized by level of priority
Clinically actionable results
Potential clinical trials
MSI stability, TMB level
Key gene amplifications and fusions
The test can be used for any cancer type but is ideal for analysis of solid tumors such as breast, lung, colon, pancreas, prostate, sarcoma, and others.
Ordering Process:
Complete the Protean MAPS® test requisition form
Send the completed test requisition form via fax or Protean’s secure electronic portal
Ship plasma or whole blood to Protean’s laboratory
Receive results within 10-15 business days
Sample Requirements:
Tissue block, or 10 or more slides.
Details for slides: UNBAKED, 5 micron thick sections
Details for tissue block: Should allow for 10 slides to be cut from the tissue block.
Mutation Detection Sensitivity:
Protean 600+ can detect down to 3% for non hotspots, and 1% for hotspots.
The Protean MAPS® System
Protean 600+ is part of Protean’s full molecular analysis system for cancer.
Protean MAPS® includes Methylation, pathology review, IHC, rapid IDH1/2 mutation testing, NGS profiling and complex fusion analysis
Order Protean 600+
Fill out your name and email address below and someone from Protean’s support team will be in touch shortly.
References
Zhang H, Qureshi M, Wahid M, Charifa A, Ehsan A, IP A, De Dios I, Ma W, McCloskey J, Donato M, Siegel D, Gutierrez, Pecora A, Goy A, Albitar M. Differential diagnosis of hematologic and solid tumors using targeted Transcriptome and artificial intelligence (In press).
Rassy E, Pavlidis N. Progress in refining the clinical management of cancer of unknown primary in the molecular era. Nat Rev Clin Oncol. 2020;17(9):541–554. doi: 10.1038/s41571-020-0359-1.
Varadhachary GR, Raber MN. Cancer of unknown primary site. N Engl J Med. 2014;371(21):757–765. doi: 10.1056/NEJMc1411384.
